853995-86-5

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 2436-90-0 (S)-(+)-dihydromyrcene 
• 853996-00-6 (2R,3S,5S,6R)-2-[2-Bromo-6-(tert-butyl-dimethyl-silanyloxy)-3,5-dimethoxy-4-methyl-phenyl]-3,5-dimethyl-6-((S)-3-methyl-pent-4-enyl)-tetrahydro-pyran-4-one 
• 853995-89-8 {3-Bromo-4,6-dimethoxy-5-methyl-2-[(2R,5S,6R)-5-methyl-4-methylene-6-((S)-3-methyl-pent-4-enyl)-[1,3]dioxan-2-yl]-phenoxy}-tert-butyl-dimethyl-silane 
• 853995-90-1 (2R,3S,6R)-6-[2-Bromo-6-(tert-butyl-dimethyl-silanyloxy)-3,5-dimethoxy-4-methyl-phenyl]-3-methyl-2-((S)-3-methyl-pent-4-enyl)-tetrahydro-pyran-4-one 
• 853995-99-0 (2R,5S,6R)-2-[2-Bromo-6-(tert-butyl-dimethyl-silanyloxy)-3,5-dimethoxy-4-methyl-phenyl]-5-methyl-6-((S)-3-methyl-pent-4-enyl)-[1,3]dioxan-4-one 
• 853995-98-9 (S)-4-Benzyl-3-((2S,3R,6S)-3-hydroxy-2,6-dimethyl-oct-7-enoyl)-oxazolidin-2-one 
• 853995-87-6 2-bromo-6-(tert-butyl-dimethyl-silanyloxy)-3,5-dimethoxy-4-methyl-benzaldehyde 
• 853995-97-8 2-bromo-6-hydroxy-3,5-dimethoxy-4-methyl-benzaldehyde 
• 853995-88-7 (2S,3R,6S)-3-Hydroxy-2,6-dimethyl-oct-7-enoic acid 
• 853996-01-7 (2R,3R,4S,5R,6R)-2-[2-Bromo-6-(tert-butyl-dimethyl-silanyloxy)-3,5-dimethoxy-4-methyl-phenyl]-3,5-dimethyl-6-((S)-3-methyl-pent-4-enyl)-tetrahydro-pyran-4-ol 
• 69739-34-0 t-butyldimethylsiyl triflate 
• 85071-58-5 2-hydroxy-3,5-dimethoxy-4-methylbenzaldehyde 
• 93904-58-6 (S)-4-methyl-5-hexenal 

Downstream Products

• 853995-91-2 (3S,5S)-1-{3-(tert-Butyl-dimethyl-silanyloxy)-2-[(2R,3S,4S,5S,6R)-4-(tert-butyl-dimethyl-silanyloxy)-3,5-dimethyl-6-((S)-3-methyl-pent-4-enyl)-tetrahydro-pyran-2-yl]-4,6-dimethoxy-5-methyl-phenyl}-3,5,7-trimethyl-oct-7-en-2-ol 
• 183202-73-5 (5R,6R,7S,8R,9R,12S,13E,16S,18S,19S)-6,7,8,9,10,11,12,15,16,17,18,19-dodecahydro-4,7,19-trihydroxy-2,6,8,12,14,16,18-heptamethyl-1,19:5,9-diepoxybenzo[18]annulen-3(5H)-one 

Relevant academic research and scientific papers

Evolution of a total synthesis of (-)-kendomycin exploiting a Petasis-Ferrier rearrangement/ring-closing olefin metathesis strategy

A convergent stereocontrolled total synthesis of (-)-kendomycin (1) has been achieved. The synthesis proceeds with a longest linear sequence of 21 steps, beginning with commercially available 2,4-dimethoxy-3-methylbenzaldehyde (12). Highlights of the synthesis include an effective Petasis-Ferrier union/rearrangement tactic to construct the sterically encumbered tetrahydropyran ring, a ring-closing metathesis to generate the C(4a-13-20a) macrocycle, an effective epoxidation/deoxygenation sequence to isomerize the C(13,14) olefin, and a biomimetic quinone-methide-lactol assembly to complete the synthesis.

Rapid stereocontrolled assembly of the fully substituted C-aryl glycoside of kendomycin with a Prins cyclization: A formal synthesis

Prins cyclization using an electron-rich benzaldehyde and a homoallylic alcohol efficiently delivered the fully substituted C-aryl tetrahydropyranoside of kendomycin. The Royal Society of Chemistry 2006.

Total synthesis of (-)-kendomycin exploiting a petasis-ferrier rearrangement/ring-closing olefin metathesis synthetic strategy

The total synthesis of (-)-kendomycin (1), a novel macrocyclic polyketide with antibacterial and antitumor activity, was achieved in 21 steps (longest linear sequence) exploiting an effective Petasis-Ferrier union/rearrangement tactic to construct the tet